Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2016-11-26
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of Selinexor when given together
with decitabine in treating patients with acute myeloid leukemia that has returned after
treatment (relapsed) or does not respond to treatment (refractory). Drugs used in
chemotherapy, such as decitabine and Selinexor, work in different ways to stop the growth of
cancer cells, either by killing the cells or by stopping them from dividing.